SG11201407682TA - Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators - Google Patents
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulatorsInfo
- Publication number
- SG11201407682TA SG11201407682TA SG11201407682TA SG11201407682TA SG11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- receptor modulators
- glucocorticoid receptor
- heteroaryl
- fused azadecalin
- Prior art date
Links
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 235000001543 Corylus americana Nutrition 0.000 abstract 1
- 240000007582 Corylus avellana Species 0.000 abstract 1
- 235000007466 Corylus avellana Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- -1 heteroaryl ketone Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Electroluminescent Light Sources (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651669P | 2012-05-25 | 2012-05-25 | |
| US201261691083P | 2012-08-20 | 2012-08-20 | |
| US201261715907P | 2012-10-19 | 2012-10-19 | |
| US201361759520P | 2013-02-01 | 2013-02-01 | |
| US201361781629P | 2013-03-14 | 2013-03-14 | |
| PCT/US2013/042732 WO2013177559A2 (en) | 2012-05-25 | 2013-05-24 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407682TA true SG11201407682TA (en) | 2014-12-30 |
Family
ID=49624542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407682TA SG11201407682TA (en) | 2012-05-25 | 2013-05-24 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Country Status (24)
| Country | Link |
|---|---|
| EP (6) | EP4119561B1 (enExample) |
| JP (1) | JP6172871B2 (enExample) |
| KR (1) | KR102062640B1 (enExample) |
| CN (1) | CN104619328B (enExample) |
| AU (1) | AU2013266110C1 (enExample) |
| BR (1) | BR112014028857B1 (enExample) |
| CA (1) | CA2872260C (enExample) |
| CL (1) | CL2014003173A1 (enExample) |
| DK (5) | DK3338781T3 (enExample) |
| ES (5) | ES2873949T3 (enExample) |
| FI (1) | FI4119561T3 (enExample) |
| HK (1) | HK1250014B (enExample) |
| IL (1) | IL235868A (enExample) |
| MX (1) | MX365423B (enExample) |
| MY (1) | MY172739A (enExample) |
| NZ (1) | NZ701469A (enExample) |
| PE (1) | PE20150352A1 (enExample) |
| PH (1) | PH12014502584B1 (enExample) |
| PL (5) | PL2854814T3 (enExample) |
| PT (5) | PT2854814T (enExample) |
| RU (1) | RU2639867C2 (enExample) |
| SG (1) | SG11201407682TA (enExample) |
| WO (1) | WO2013177559A2 (enExample) |
| ZA (1) | ZA201408182B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| RU2674983C1 (ru) * | 2013-11-25 | 2018-12-14 | Корсепт Терапеутикс, Инк. | Октагидро конденсированные азадекалиновые модуляторы глюкокортикоидного рецептора |
| CA2977591C (en) * | 2015-03-02 | 2024-09-10 | Corcept Therapeutics Inc | Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors |
| ES2906778T3 (es) | 2015-03-30 | 2022-04-20 | Corcept Therapeutics Inc | Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal |
| IL309712A (en) * | 2015-05-18 | 2024-02-01 | Corcept Therapeutics Inc | Methods for diagnosing and determining treatment for Cushing's syndrome |
| MX383318B (es) * | 2015-08-13 | 2025-03-13 | Corcept Therapeutics Inc | Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina. |
| KR102845317B1 (ko) | 2016-03-01 | 2025-08-13 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도 |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| KR102342620B1 (ko) | 2017-03-31 | 2021-12-22 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제 |
| US11213526B2 (en) | 2017-06-20 | 2022-01-04 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
| CA3098118C (en) * | 2018-04-23 | 2023-09-05 | Corcept Therapeutics, Inc. | Methods of preparing regioselective n-alkyl triazoles |
| WO2020097513A1 (en) | 2018-11-09 | 2020-05-14 | Corcept Therapeutics Incorporated | Methods for shrinking pituitary tumors |
| SG11202105770YA (en) | 2018-12-19 | 2021-07-29 | Corcept Therapeutics Inc | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| WO2020132171A1 (en) * | 2018-12-20 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods for imaging and treatment of somatostatin-receptor positive tumors |
| EP3927345A4 (en) | 2019-02-22 | 2022-12-21 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| EP4045045A4 (en) * | 2019-10-16 | 2023-11-22 | Corcept Therapeutics Incorporated | METHOD FOR NORMALIZING THE RATIO BETWEEN NEUTROPHILS AND LYMPHOCYTES IN CANCER PATIENTS USING A SELECTIVE GLUCOCORTICOID RECEPTOR ANTAGONIST |
| EP4072556A4 (en) | 2019-12-11 | 2024-01-03 | Corcept Therapeutics Incorporated | METHODS OF TREATING ANTIPSYCHOTIC DRUG-INDUCED WEIGHT GAIN WITH MIRICORILANT |
| EP4076470B1 (en) | 2019-12-21 | 2025-12-03 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
| KR20220140567A (ko) * | 2020-02-10 | 2022-10-18 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 선택적 글루코코르티코이드 수용체 조절제를 사용하여 항-종양 반응을 자극하는 방법 |
| WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2022166810A1 (zh) * | 2021-02-03 | 2022-08-11 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| CN119997939A (zh) * | 2022-10-06 | 2025-05-13 | 科赛普特治疗公司 | 糖皮质激素受体调节剂的制剂 |
| CN120202004A (zh) | 2022-10-28 | 2025-06-24 | 科赛普特治疗学股份有限公司 | 使用达祖可兰治疗肌萎缩侧索硬化症 |
| AU2024223250A1 (en) * | 2023-02-17 | 2025-08-14 | Corcept Therapeutics Incorporated | Methods and compositions for treating huntington's disease and its symptoms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| ATE407934T1 (de) | 2004-03-09 | 2008-09-15 | Corcept Therapeutics Inc | Azadecalinverbindungen mit kondensiertem ring als glucocorticoidrezeptormodulatoren |
| US7640389B2 (en) * | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
| EP1932843A1 (en) * | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| JP2013536250A (ja) * | 2010-08-27 | 2013-09-19 | コーセプト セラピューティクス， インコーポレイテッド | ピリジル−アミン縮合アザデカリンモジュレーター |
-
2013
- 2013-05-24 JP JP2015514233A patent/JP6172871B2/ja active Active
- 2013-05-24 MX MX2014014239A patent/MX365423B/es active IP Right Grant
- 2013-05-24 ES ES19188885T patent/ES2873949T3/es active Active
- 2013-05-24 DK DK18154256T patent/DK3338781T3/da active
- 2013-05-24 BR BR112014028857-7A patent/BR112014028857B1/pt active IP Right Grant
- 2013-05-24 CA CA2872260A patent/CA2872260C/en active Active
- 2013-05-24 KR KR1020147036405A patent/KR102062640B1/ko active Active
- 2013-05-24 DK DK13793417.0T patent/DK2854814T3/en active
- 2013-05-24 AU AU2013266110A patent/AU2013266110C1/en active Active
- 2013-05-24 ES ES22193438T patent/ES2995026T3/es active Active
- 2013-05-24 DK DK19188885.8T patent/DK3590517T3/da active
- 2013-05-24 DK DK22193438.3T patent/DK4119561T3/da active
- 2013-05-24 EP EP22193438.3A patent/EP4119561B1/en active Active
- 2013-05-24 PT PT137934170T patent/PT2854814T/pt unknown
- 2013-05-24 PT PT221934383T patent/PT4119561T/pt unknown
- 2013-05-24 FI FIEP22193438.3T patent/FI4119561T3/fi active
- 2013-05-24 RU RU2014152625A patent/RU2639867C2/ru active
- 2013-05-24 PL PL13793417T patent/PL2854814T3/pl unknown
- 2013-05-24 EP EP18154256.4A patent/EP3338781B1/en active Active
- 2013-05-24 EP EP13793417.0A patent/EP2854814B1/en active Active
- 2013-05-24 PL PL22193438.3T patent/PL4119561T3/pl unknown
- 2013-05-24 PE PE2014002054A patent/PE20150352A1/es active IP Right Grant
- 2013-05-24 PT PT211546650T patent/PT3851107T/pt unknown
- 2013-05-24 PT PT181542564T patent/PT3338781T/pt unknown
- 2013-05-24 PL PL19188885T patent/PL3590517T3/pl unknown
- 2013-05-24 EP EP19188885.8A patent/EP3590517B1/en active Active
- 2013-05-24 EP EP24192650.0A patent/EP4434584A3/en active Pending
- 2013-05-24 DK DK21154665.0T patent/DK3851107T3/da active
- 2013-05-24 CN CN201380039218.1A patent/CN104619328B/zh active Active
- 2013-05-24 ES ES13793417.0T patent/ES2665338T3/es active Active
- 2013-05-24 EP EP21154665.0A patent/EP3851107B1/en active Active
- 2013-05-24 PL PL21154665.0T patent/PL3851107T3/pl unknown
- 2013-05-24 ES ES18154256T patent/ES2753816T3/es active Active
- 2013-05-24 MY MYPI2014003289A patent/MY172739A/en unknown
- 2013-05-24 ES ES21154665T patent/ES2930298T3/es active Active
- 2013-05-24 PT PT191888858T patent/PT3590517T/pt unknown
- 2013-05-24 PL PL18154256T patent/PL3338781T3/pl unknown
- 2013-05-24 NZ NZ701469A patent/NZ701469A/en unknown
- 2013-05-24 SG SG11201407682TA patent/SG11201407682TA/en unknown
- 2013-05-24 WO PCT/US2013/042732 patent/WO2013177559A2/en not_active Ceased
-
2014
- 2014-11-10 ZA ZA2014/08182A patent/ZA201408182B/en unknown
- 2014-11-19 PH PH12014502584A patent/PH12014502584B1/en unknown
- 2014-11-21 CL CL2014003173A patent/CL2014003173A1/es unknown
- 2014-11-23 IL IL235868A patent/IL235868A/en active IP Right Grant
-
2018
- 2018-07-23 HK HK18109510.2A patent/HK1250014B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201407981RA (en) | Compositions comprising an anti-pdgf aptamer and a vegf antagonist | |
| SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811149TA (en) | METABOLIC DRUG LOADING OF EVs | |
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
| SG11201808729WA (en) | Bet protein degraders | |
| SG11201804162WA (en) | Compositions comprising bacterial strains | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201408261UA (en) | Syringe | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201407372UA (en) | Nampt inhibitors | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201407710VA (en) | Compositions comprising short-acting benzodiazepines | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds |